Antisense drug firm AVI BioPharma said this week that chairman and CEO Denis Burger has resigned.
In a statement, Burger said he is retiring.
Jack Bowman, AVI’s independent lead director, has been named chairman, while another independent director, Michael Forrest, has been named interim CEO.
"Denis Burger has made a tremendous contribution to the growth and development of AVI,” Bowman said in a statement. "The board has full confidence in AVI's executive team and we look forward to working with Mike Forrest in selecting a new leader to expand the company's footprint, accelerate selection and development of clinical candidates, and improve our market opportunities."